Cover Image

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Introduction: Janus kinase inhibitors (JAK-i), a class of targeted synthetic disease-modifying antirheumatic drugs (tDMARDs), are suggested as second or third-line therapies in rheumatoid arthritis (RA). Synthesized cost-effective evidence would aid in informed decision-making given the similar clin...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. Sajith Kumar (Author), Madhumitha Haridoss (Author), Krishnamurthy Venkataraman (Author), Bhavani Shankara Bagepally (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context
by: Bhavani Shankara Bagepally, et al.
Published: (2021)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022)

Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
by: A. E. Cheberda, et al.
Published: (2024)

Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2024)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
by: Qige Wei, et al.
Published: (2023)

Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation
by: Xiaolan Shen, et al.
Published: (2024)

Is State-Wise Healthcare Budget Allocation Consistent With the Disease Burden in India? A Quinquennial Account (2015-2019)
by: Bhavani Shankara Bagepally, et al.
Published: (2022)

A perspective on trends in air pollution attributed disease burden in India-Authors' reply
by: S Sajith Kumar, et al.
Published: (2022)

Air pollution attributed disease burden and economic growth in India: Estimating trends and inequality between states
by: Sajith Kumar S, et al.
Published: (2022)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
by: Martin E. Dowty, et al.
Published: (2019)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023)

PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors
by: C. Garufi, et al.
Published: (2024)

Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
by: Cynthia Said, et al.
Published: (2013)

Electronic versus paper-based data collection for conducting health-care research: A cost-comparison analysis
by: Sirshendu Chaudhuri, et al.
Published: (2022)

Fournier's gangrene that initially mimicked pubic cellulitis in an elderly woman administered a Janus kinase inhibitor, methotrexate, and prednisolone for rheumatoid arthritis
by: Takahiro Shiratori, et al.
Published: (2020)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
by: Yun-Kyoung Song, et al.
Published: (2022)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
by: Irma Convertino, et al.
Published: (2023)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023)

Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Paul Langley
Published: (2020)

Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study
by: Masahiko Miyashiro, et al.
Published: (2024)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
by: David Nash, BHSc, et al.
Published: (2023)

Role of janus kinase inhibitors in the treatment of alopecia areata
by: Triyangkulsri K, et al.
Published: (2018)

Janus kinase inhibitors - their current applications and future prospects
by: Natalia Wierzbowska, et al.
Published: (2022)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023)

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
by: Michalina Grzelka, et al.
Published: (2024)

Association between chronotype and cardio-vascular disease risk factors: A systematic review and meta-analysis
by: Ditipriya Bhar, et al.
Published: (2022)

Indirect costs of the Rheumatoid arthritis in Poland
by: Emilia Howoruszko, et al.
Published: (2019)

Indirect costs of the Rheumatoid arthritis in Poland
by: Emilia Howoruszko, et al.
Published: (2019)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
by: Singer J, et al.
Published: (2016)

Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis
by: Kevin P. Lee, et al.
Published: (2023)

The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
by: Indra Wijaya, et al.
Published: (2021)

Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials
by: Wenting Cai, et al.
Published: (2024)

EMERGING USE OF JANUS KINASE INHIBITORS FOR ORAL LICHEN PLANUS
by: Mihaela Paula Toader, et al.
Published: (2024)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr
Published: (2022)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
by: Carine M. Lama, MS, et al.
Published: (2023)